31.2 C
Vientiane
Saturday, April 26, 2025
spot_img
Home Blog Page 547

HKCriminalLawyers.com Officially Launched to Provide Professional Legal Support in Criminal Cases

HONG KONG SAR – Media OutReach Newswire – 13 February 2025 – The HKCriminalLawyers.com platform has officially launched, providing Hong Kong citizens with a dedicated resource for criminal legal information and professional lawyer-matching services. Specializing in a wide range of criminal cases—including theft, fraud, assault, drug-related offenses, money laundering, and illegal gambling—the platform aims to assist individuals facing legal trouble by offering clear guidance and access to experienced lawyers.
A One-Stop Criminal Law Information Platform
Being charged with a criminal offense can be a stressful and overwhelming experience. HKCriminalLawyers.com is designed to help defendants and their families better understand their legal situation by providing:
  • Detailed Explanations of Criminal Offenses – The platform offers in-depth explanations of common offenses such as drug trafficking, theft, and fraud, covering legal definitions, relevant laws, sentencing guidelines, and possible defenses.
  • Sentencing Standards and Case Analysis – Based on previous court cases, HKCriminalLawyers.com provides sentencing benchmarks to help individuals understand how penalties are determined. For instance, in money laundering cases, penalties can reach up to 14 years of imprisonment, with factors such as transaction amounts and intent influencing the severity of the sentence.
  • Plea Strategies and Defense Tactics – Those seeking to reduce penalties can find useful resources on writing a mitigation letter, including examples of successful plea letters and key points that courts consider during sentencing.
Professional Lawyer Matching Services
Beyond legal information, HKCriminalLawyers.com offers a lawyer-matching service, helping individuals connect with experienced criminal defense lawyers suited to their case type, financial situation, and legal needs. The platform ensures that all partner lawyers are licensed professionals with extensive experience in handling criminal cases.
For cases such as drug offenses or assault charges, which may involve police arrests and bail applications, the website provides step-by-step guidance on applying for bail, understanding bail conditions, and preparing for court appearances. Additionally, it features a police statement guide to help individuals understand their rights when being questioned by the police.
24/7 Legal Consultation and Emergency Support
Criminal cases can happen unexpectedly, and HKCriminalLawyers.com ensures that individuals receive immediate legal assistance when needed. The platform offers a 24/7 emergency support service, allowing individuals to contact legal professionals in urgent situations such as police arrests, house searches, or urgent court hearings.
Those in need of urgent legal consultation can use the platform to connect directly with experienced lawyers for immediate support.
Future Expansion and Services
HKCriminalLawyers.com plans to continuously expand its services by covering a broader range of criminal offenses and introducing interactive features such as a criminal case Q&A tool, which will allow users to obtain preliminary legal advice without revealing personal details. Additionally, the platform is exploring partnerships with more Hong Kong-based law firms to improve its lawyer-matching service and provide faster, more effective legal assistance.

With the launch of HKCriminalLawyers.com, individuals in Hong Kong now have access to a professional and user-friendly platform for understanding criminal law and connecting with experienced defense lawyers. Whether someone is searching for legal representation or simply seeking to understand their legal rights, HKCriminalLawyers.com provides a reliable and trustworthy resource.
For more information, visit HKCriminalLawyers.com for immediate assistance.

Hashtag: #HKCriminalLawyers

The issuer is solely responsible for the content of this announcement.

XDENT LAB Expands the Largest Removable Denture Factory in Vietnam – Forecasting Strong Growth, Pioneering Dental Lab-to-Lab Services for the U.S. Market

HO CHI MINH CITY, Vietnam, Feb. 13, 2025 /PRNewswire/ — XDENT LAB, one of the leading providers in the field of Removable Denture manufacturing in Vietnam, has officially announced the expansion of its production facility, making it the largest in the country. This strategic move not only marks a significant leap for XDENT LAB in the dental industry but also reinforces its pioneering position in Lab-to-Lab services, targeting the U.S. market.

XDENT LAB started as a CAD design center in 2017. By 2019, the company had invested in state-of-the-art equipment, transforming itself into a full-service Dental Lab specializing in serving U.S. partners. Through continuous development and the enhancement of its core workforce, XDENT LAB has established itself as Vietnam’s leading partner for dental labs in the United States.

Enhancing Processes, Expanding Scale

XDENT LAB’s new facility is strategically designed to optimize the production process of Removable Dentures, meeting the strict standards of the U.S. market, with a total area of 1,500m². Over the years, the company has meticulously refined its production process, prioritizing strict procedural compliance to ensure consistent quality and on-time delivery.

This expansion allows XDENT LAB to boost its production capacity, providing faster and more efficient services to international partners looking for a reliable Vietnam Dental Lab. The increased capacity also enables the company to meet the growing demand from the U.S. market, where precision and quality are paramount.

XDENT LAB’s production process is optimized according to Lean Manufacturing principles, ensuring the following commitments:

  1. Commit to 100% FDA-Approved Materials – Utilizing high-quality materials while optimizing inventory for maximum efficiency and cost reduction.
  2. Commit to Large-Scale Manufacturing, high volume, remake rate < 1%.
  3. Commit to 2~3 days in lab (*digital file)
  4. Commit to Cost Savings 30% for partners through an intelligent workforce utilization model
  5. Commit to Uninterrupted Manufacturing 365 days a year

Pioneering the Lab-to-Lab Model

Beyond expanding production capacity, XDENT LAB is also a leader in developing the Lab-to-Lab model, an optimized outsourcing solution for U.S. dental labs. Through an advanced online communication portal, clients can effortlessly place orders, track progress, and receive personalized customer support from XDENT LAB’s team.

“We understand that U.S. dental labs seek high-quality production solutions while maintaining cost efficiency. With our Lab-to-Lab model, XDENT LAB not only delivers internationally certified products but also creates seamless connectivity, helping our partners operate more effectively,” said CEO Alex Tran, representing XDENT LAB.

Strategic Expansion for Global Reach

With the largest Removable Denture factory in Vietnam, along with a geopolitical advantage for trade with the U.S. and a young, skilled workforce, XDENT LAB is not only strengthening its domestic position but also creating opportunities to compete with other countries in the Asia-Pacific region.

Vision & Mission, Business Philosophy, Core Values

Mission

We aspire to elevate Vietnam as a global leader in the Dental Lab industry, becoming the trusted choice for Dental Labs and Dental Clinics.

Vision

Our goal is to become the #1 Lab-to-Lab brand globally and the top Removable Denture provider in the U.S. market.

Business Philosophy

  • Serving the community – We are committed to contributing, sharing, and helping with a spirit of generosity.
  • Win-Win Together – We follow a win-win philosophy, ensuring balanced benefits: for our company, our partners, and the community.
  • “Trust” as our guiding principle – We place “Trust” at the forefront of every business activity.

Core Values – What We Stand For

  • Kindness – We believe in the inherent goodness of people. Therefore, we continuously nurture and spread this value through our daily actions and decisions. Think good – Do good, together we create a sustainable and humane business environment.
  • Compliance – Discipline and compliance are the foundation of sustainable development. We strictly adhere to production procedures and workplace regulations, ensuring product consistency and building a professional, transparent, and trustworthy work environment.
  • Dedication – We believe that commitment and wholehearted service make us a trusted, professional, and distinguished company. This is the foundation of our outstanding customer service.

XDENT LAB Services

XDENT LAB specializes in Removable Denture services, offering:

  • Full/Partial Removable Dentures – Available in a variety of materials including Acrylic, Thermoplastic, Metal, Acetal, Gold, etc.
  • Restoration support products such as Bite Rim, Bite Block
  • Temporary removable dentures including Stayplate, Flipper
  • Support appliances such as Night Guard, Sport Guard
  • Orthodontic appliances such as Clear Aligner, Retainer

XDENT LAB is approved-FDA for manufacturing, ensuring that all products meet import standards for the U.S. market.

For more information, visit our website at www.xdentlab.com and follow us on social media:

For more information, please contact XDENT LAB via:
– Website: www.xdentlab.com
– Email: cs@xdentlab.com 
– Telephone/ WhatsApp: (+84) 919 796 718

Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground

  • Milestone reaffirms Hyundai Motor Group’s commitment to safety, quality, design, and performance
  • More than 5,000 vehicles have been tested and driven more than 20-million miles at the facility since opening in 2005
  • 20-year celebratory event and reception was held on Monday, Feb. 10 

CALIFORNIA CITY, Calif., Feb. 13, 2025 /PRNewswire/ — Hyundai America Technical Center, Inc. (HATCI) held a celebration event earlier this week in honor of 20 successful years of quality and performance testing at its California Proving Ground (CPG) in California City, Calif. The $80 million facility, which opened in 2005, has seen more than 5,000 Hyundai Motor, Kia, and Genesis vehicles undergo rigorous testing on a variety of roads and in extreme conditions to ensure their quality, durability, reliability, and safety.

Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground
Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground

“The Hyundai Motor Group has made exceptional progress over the past 20 years, thanks in part to our California Proving Ground and the outstanding work of our team there,” said Euisun Chung, Executive Chair, Hyundai Motor Group. “As we look to the future, we must focus on pioneering technologies such as AI, robotics, Software Defined Vehicles, electrification, and hydrogen technology. Facilities like the California Proving Ground will be critical to that innovation and will help shape the next 20 years of Hyundai Motor Group, turning challenges into opportunities and setbacks into successes.”

Situated in the middle of the Mojave Desert, the HATCI CPG is a 4,500-acre facility that serves as the center for Hyundai Motor, Kia, and Genesis vehicle evaluation operations in North America. The grounds include a 6.4-mile oval track, 2-million square-foot Vehicle Dynamics Area (VDA), 2.75-mile winding road track, a 3.3-mile hill road, off-road evaluation loops, and various specially surfaced roads exactingly constructed to replicate U.S. highways.

Team members at the facility perform full vehicle evaluation, durability, and development testing. Vehicle development operations include activities ranging from ride and handling evaluations to Noise, Vibration, and Harshness (NVH) tests and Heat Protection assessments. The CPG also features three fully equipped garages and a material-weathering facility to accelerate and assess UV degradation.

The CPG is one of many HATCI facilities in the United States dedicated to design, technology and engineering of Hyundai Motor Group (HMG) vehicles. HATCI supports new model development for HMG’s North American operations and global programs from dedicated engineering facilities and support staff at affiliate sites located throughout the United States.

 

Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground
Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground

Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground
Hyundai Motor Group Celebrates 20 Years of Driving Innovation at the Hyundai California Proving Ground

Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa

  • The first optogenetic “Chimeric Rhodopsin” gene therapy tested in humans.
  • RV-001 starting dose was generally well tolerated in this open-label trial.
  • RV-001 a gene-agnostic approach for RP patients.

TOKYO, Feb. 13, 2025 /PRNewswire/ — Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed at Keio University Hospital. RV-001 utilizes adeno-associated virus (AAV) vectors to deliver a unique functional gene encoding “Chimeric Rhodopsin”, a light-driven G-protein activation mechanism to re-establish light activation in retinal interneurons. The goal is to expand light sensitivity to retinal interneurons via an intravitreal injection of RV-001. This milestone marks the initiation of the world’s first clinical trial of optogenetic gene therapy, which leverages a proprietary “Chimeric Rhodopsin” for patients with retinitis pigmentosa (RP). “Over 2 million people worldwide suffer photoreceptor loss in retinitis pigmentosa, resulting in severe vision loss and eventual blindness” said, CEO and Ophthalmologist Yusaku Katada, MD, PhD. “Our “chimeric rhodopsin” approach has broad potential to alter light sensitivity across multiple subtypes of RP patients.[1] We are continuing to advance the Phase I/II trial to assess safety, light-activation and light-sensitivity in these patients, post-administration of our lead gene therapy product RV-001.”

Phase I/II Safety, Tolerability, and Exploratory Efficacy Trial Highlights

  • Patient Criteria: Participants with advanced RP, agnostic to genotype, and characterized by severe vision loss, no- to limited vision.
  • Safety and Efficacy: In addition to safety, exploratory efficacy endpoints include improvements in light sensitivity and visual function.

Connecting Innovation, Academia, and Investment 

Restore Vision, Inc., a spin-out startup from Keio University, bridges cutting-edge academic innovation with entrepreneurial application to drive progress in retinal therapies. Developed through collaborations with Keio University School of Medicine and Nagoya Institute of Technology, RV-001’s optogenetic technology addresses the limitations of traditional approaches by combining high light sensitivity with a unique G-protein activation mechanism.[2],[3] This groundbreaking technology has the potential to be expanded to other retinal diseases, paving the way for broader applications in vision restoration. The Japan Agency for Medical Research and Development (AMED) and other academic grants, with key contributions from Keio University and Nagoya Institute of Technology, supported RV-001 development.

About Restore Vision

Restore Vision Inc., a clinical-stage gene therapy company, specializes in developing transformative gene therapies for inherited retinal disorders. By integrating academic excellence with entrepreneurial vision, the company is committed to pioneering treatments that address critical unmet medical needs and improve patient outcomes worldwide.

Media Contact

Hikaru Miyazaki
COO, Restore Vision Inc.
Email: contact@restore-vis.com 

[1] Roberts et al. Arch Ophthalmol. 2010

[2] Sasaki et al. PLoS One. 2014

[3] Katada et al. iScience. 2023

 

Aker Horizons ASA: Fourth-quarter results 2024

FORNEBU, Norway, Feb. 13, 2025 /PRNewswire/ — Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, today announced results for the fourth quarter 2024. Aker Horizons’ net capital employed stood at NOK 5.9 billion, a decrease of NOK 0.2 billion from the third quarter, mainly reflecting AKH’s share of results in the portfolio companies in Q4. The company reported a cash position of NOK 2.9 billion and an undrawn credit facility of EUR 500 million, giving available liquidity of NOK 8.8 billion.

Main developments in the portfolio:

Aker Carbon Capture has proposed a dividend of NOK 3.5 billion, and reports a new contract award in SLB Capturi:

– The Board of Directors of ACC ASA has proposed a dividend of NOK 3.5 billion (NOK 1.5 billion to AKH), subject to approval by ACC ASA’s general meeting.

– SLB Capturi has reached significant industrial milestones with the hand-over of the modular carbon capture facility at Twence, and the award of an EPCIC contract for a Just Catch 400 unit to Hafslund Celsio.

Mainstream Renewable Power reports projects in South Africa progressing toward COD, and an improved commercial margin in the Andes portfolio:

– Two projects for a combined ~150 MW under construction in South Africa are progressing toward COD in Q2 2025 and early 2026.

– The commercial margin in the Andes portfolio in Chile showed continued positive development in Q4.

– Cost optimization initiatives are well underway targeting a ~65% decrease in payroll and overhead cost.

Aker Horizons Asset Development signed a term sheet for offtake from Narvik Green Ammonia (NGA), and is developing the Powered Land business:

– A term sheet for 150 ktpa offtake from NGA was signed with VNG.

– A collaboration agreement was signed with a major European utility targeting an ownership share in NGA post DG2.

– The Kvandal site in Northern Norway is ready-to-build with 230 MW for power intensive industries.

SuperNode is planning the full-scale testing of their superconducting technology this year:

– A full-scale prototype of SuperNode’s superconducting system is to be tested in the company’s own facility H1 2025.

– A first full-scale demo in a real TSO environment is to be conducted at the National Grid Deeside facility later in 2025.

Aker Horizons reports net capital employed to reflect a portfolio composed mainly of unlisted assets. Net capital employed includes Aker Horizons’ initial investment in the portfolio company, adjusted for any profit or loss and any additional investments, adjusted for foreign exchange fluctuations. As of the fourth quarter, Aker Horizons had NOK 2.4 billion net capital employed in ACC, NOK 2.5 billion in Mainstream, NOK 524 million in AAD, NOK 210 million in SuperNode and NOK 365 million in other assets.

The Q4 2024 presentation is attached.

Aker Horizons’ CEO Lars P. Sørvaag Sperre and CFO Kristoffer Dahlberg, and Mainstream’s CFO Julie Berg will present the main developments in the fourth quarter 2024 today at 08:30 CET, followed by a Q&A session. The presentation, which is open to all, will be held in English and will be webcast on Aker Horizons’ website: 
https://akerhorizons.com/investors 

For further information, please contact:
Jonas Gamre, Investor Relations, tel: +47 97 11 82 92, email: jonas.gamre@akerhorizons.com
Mats Ektvedt, Media, tel: +47 41 42 33 28, email: mats.ektvedt@corporatecommunications.no 

About Aker Horizons

Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com 

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements in Regulation EU 596/2014 and the Norwegian Securities Trading Act § 5-12. This stock exchange announcement was published by Mats Ektvedt, Partner in Corporate Communications, on 13 February 2025 at 07:00 CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aker-horizons/r/aker-horizons-asa–fourth-quarter-results-2024,c4104928

The following files are available for download:

 

Cloud4C Secures Dual AI Specializations on Microsoft Azure, Strengthening AI Capabilities

SINGAPORE, Feb. 13, 2025 /PRNewswire/ — Cloud4C, a global leader in AI-driven cloud and cybersecurity services, has achieved two prestigious AI specializations on Microsoft Azure: ‘AI Platform on Microsoft Azure’ and ‘Build AI Apps on Microsoft Azure’. This milestone reinforces Cloud4C’s expertise in deploying AI workloads, implementing Azure’s AI services, and designing enterprise AI solutions while ensuring security, compliance, and scalability.

Advancing AI-First Enterprise Strategies with Microsoft Azure

These exclusive certifications recognize Cloud4C’s proven capabilities in building, deploying, and managing AI solutions on Azure. “Earning this specialization shows our ability to implement Azure’s AI services and design Sovereign AI solutions, while also delivering secure, scalable, and fully managed AI deployments tailored to business needs,” said Chanakya Levaka, Chief Operating Officer, Cloud4C. “With Microsoft Azure as our strategic partner, we empower enterprises to seamlessly integrate AI into their transformation strategies. As part of this commitment, Cloud4C has successfully deployed Microsoft Security Copilot for SIEM across key industries, including aviation, cargo handling, and energy. Leveraging real-time threat intelligence, automated incident analysis, and proactive response capabilities, Cloud4C is helping enterprises strengthen cybersecurity defenses and stay ahead of evolving threats with AI-driven security operations.”

Cloud4C: Delivering AI-Powered Business Impact

Cloud4C has executed enterprise-grade AI implementations such as Patient/Customer Experience platforms, Pharmacovigilance, RCA analysis, AI Agentic Framework for underwriters, AI-powered contact centers, conversational BI, computer vision, and enterprise knowledge co-pilots and more across regulated industries such as healthcare, life sciences, insurance, banking, manufacturing, and retail. The company plays a key role in optimizing cloud infrastructure for AI, enabling intelligent process automation, powering AI-driven data analytics, and securing AI workloads.

This AI milestone also aligns with Cloud4C’s participation at the Microsoft AI Tour, Singapore (Feb 19, Marina Bay Sands), where it will showcase its cutting-edge AI capabilities.

About Cloud4C

Cloud4C is a global leader in AI and Automation-Driven Managed Services and Managed Security Services, helping 4,000+ enterprises across 30+ countries scale with confidence. We simplify cloud and AI adoption through an end-to-end managed services framework, ensuring seamless integration from infrastructure to AI-powered workloads, all backed by a 99.95% uptime SLA at application login layer.

With AI-powered automation, predictive analytics, industry specific reference architectures and deep security expertise, we drive secure, intelligent, and agile business transformation. Our cybersecurity-first approach—including MXDR, SOC, real-time threat detection, and compliance—ensures enterprises can innovate without risk.

Hugel achieves record net sales, profit, net income in 2024

– The company reports KRW373.0 billion in net sales, KRW166.3 billion in operating profit, and KRW142.4 billion in net income, reflecting year-over-year increases of 16.7%, 41.2%, and 45.8%, respectively

– More international revenue contributions to expect in 2025 with key new toxin market launch in sight, including the US and the Gulf Cooperation Council (GCC)

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ — Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, posted record-breaking earnings in 2024 with KRW373.0 billion in net sales and KRW166.3 billion in operating profit, respectively up 16.7% and 41.2% year-over-year. Net income increased 45.8% on-year to KRW142.4 billion.

In the fourth quarter alone, the company recorded KRW98.2 billion in net sales, KRW46.6 billion in operating profit, and KRW40.7 billion in net income, reflecting year-over-year growth of 10.4%, 26.7%, and 130%, respectively.

NET SALES GROWTH DRIVEN BY TOXIN, HA FILLERS, COSMETICS 

Hugel’s botulinum toxin, branded as Botulax in South Korea and globally known as Letybo, achieved KRW203.2 billion in net sales in 2024 with a 20.2% increase on-year. The overseas sales of the botulinum toxin rose 39.6% on-year, fueled by strong performance in major Asia-Pacific markets, shipment to the US, and robust growth in Europe.

Hyaluronic acid (HA) fillers, branded as THE CHAEUM and BYRYZN in South Korea and globally known as Revolax, achieved KRW127.6 billion in net sales for 2024. The overseas sales of dermal fillers rose 13.2% on-year, led by steady shipments to China and continued growth in Europe and the Middle East and North Africa (MENA). Hugel focuses on marketing activities for the fillers to increase brand awareness while maintaining leadership in South Korea and expanding its presence in global markets.

Hugel’s cosmetics business, represented by brands WELLAGE and BYRYZN BR, showed rapid growth last year. Net sales of the cosmetics business jumped 37.8% on-year to KRW36.9 billion in 2024. In the fourth quarter, net sales soared 48.1% on-year to KRW11.7 billion. Hugel is strengthening the cosmetics brand value by releasing the Hyper Peptide series of WELLAGE last August and promoting BYRYZN BR, launched in April 2024.

GLOBAL EXPANSION ACCELERATES WITH TOXIN ENTRY IN THE US, MENA, AND OTHER EMERGING MARKETS

Hugel will continue to focus on expanding sales and increasing market dominance abroad this year.

The company is prioritizing sales and marketing efforts in the US, where it plans to officially launch its botulinum toxin in the first half of the year. Hugel aims to capture 10% of the US medical aesthetics market within three years, differentiating itself through academic events for medical professionals and competitive pricing strategies.

Hugel will also accelerate its expansion in MENA, a key emerging market for medical aesthetics. The company targets a 30% share within three years in major markets, including the United Arab Emirates where it obtained a marketing license in January of this year and Kuwait where it has been present for 2.5 years.

“We achieved the highest net sales, operating profit, and net income in 2024 since our inception with significant growth in flagship products such as botulinum toxin and hyaluronic acid fillers and new growth driver cosmetics. We will continue expansion in our new markets, including North America and MENA, while strengthening our leadership position in Asia-Pacific and Europe and solidifying our position as a global industry leader”, a Hugel official said.

About Hugel

Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in South Korea, Hugel is the only South Korean company with regulatory approvals in the world’s three largest botulinum toxin markets: the US, China, and Europe. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums. Over the past 20 years, the company has built a presence in approximately 70 countries and operates eight global subsidiaries across South Korea, the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore. Leveraging strong industry momentum, Hugel is poised for continued growth and global market expansion.

Contact:
Jihyun Kim, Manager of the PR Team, Hugel
jihyun.kim@hugel-inc.com 

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ — DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

By leveraging DAAN Biotherapeutics’ next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.

DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.

Byoung Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, “We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs, we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform.”